December 4, 2022

The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer’s drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer’s disease.


Leave a Reply

Your email address will not be published. Required fields are marked *